Nuvectis Pharma rises on FDA's 'fast track' tag for ovarian cancer therapy

Nuvectis Pharma

01/12/2022 15:18

** Shares of cancer therapy developer Nuvectis Pharma Inc 
 NVCT.O  rise 9% to $8.01
    ** Co says it received U.S. FDA's "fast track" tag for its
therapy, NXP800, to treat a type of ovarian cancer    
    ** A fast track designation facilitates development and
expedites review of therapies with the potential to treat a
serious condition where there is an unmet medical need
    ** Including session's gains, stock has risen ~146% since
going public in February 
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))